

Tobias D. Henning  
Olaf Saborowski  
Daniel Golovko  
Sophie Boddington  
Jan S. Bauer  
Yanjun Fu  
Reinhard Meier  
Hubertus Pietsch  
Barbara Sennino  
Donald M. McDonald  
Heike E. Daldrup-Link

## Cell labeling with the positive MR contrast agent Gadofluorine M

Received: 3 March 2006  
Revised: 4 October 2006  
Accepted: 3 November 2006  
Published online: 6 January 2007  
© Springer-Verlag 2007

Both authors, Tobias D. Henning and Olaf Saborowski, contributed equally to this manuscript.

This work was supported in part by a Academic Senate grant from the University of California of San Francisco (D-L), stipends from the German Research Association (TDH) and from the Schering AG (OS), by the US National Institutes of Health grants HL-24136 and HL 59157 from the National, Heart, Lung, and Blood Institute, and CA082923 from the National Cancer Institute (DMcD).

T. D. Henning · O. Saborowski ·  
D. Golovko · S. Boddington ·  
J. S. Bauer · Y. Fu · R. Meier ·  
H. E. Daldrup-Link (✉)  
Department of Radiology,  
University of California in San Francisco,  
505 Parnassus Ave,  
San Francisco, CA 94143, USA  
e-mail: daldrup@radiology.ucsf.edu  
Tel.: +1-415-4765592  
Fax: +1-415-4760616

H. Pietsch  
Schering AG,  
Berlin, Germany

B. Sennino · D. M. McDonald  
Cardiovascular Research Institute,  
Comprehensive Cancer Center, and  
Department of Anatomy, University of  
California,  
San Francisco, USA

**Abstract** The purpose of this study was to label human monocytes with Gadofluorine M by simple incubation for subsequent cell depiction at 1.5 and 3 T. Gadofluorine M displays a high  $r_1$  relaxivity and is spontaneously phagocytosed by macrophages. Human monocytes were incubated with Gadofluorine M-Cy at varying concentrations and incubation times and underwent MR imaging at 1.5 and 3 T at increasing time intervals after the labeling procedure.  $R_1$ -relaxation rates and  $r_1$  relaxivities of the labeled cells and non-labeled controls were determined. Cellular contrast agent uptake was examined by fluorescence microscopy and quantified by ICP-AES. Efficient cell labeling was achieved after incubation of the cells with 25 mM Gd Gadofluorine M for

12 h, resulting in a maximal uptake of 0.3 fmol Gd/cell without impairment of cell viability. Fluorescence microscopy confirmed internalization of the fluorescent contrast agent by monocytes. The  $r_1$  relaxivity of the labeled cells was  $137 \text{ mM}^{-1}\text{s}^{-1}$  at 1.5 T and  $80.46 \text{ mM}^{-1}\text{s}^{-1}$  at 3 T. Imaging studies showed stable labeling for at least 7 days. Human monocytes can be effectively labeled for MR imaging with Gadofluorine M. Potential in vivo cell-tracking applications include targeting of inflammatory processes with Gadofluorine-labeled leukocytes or monitoring of stem cell therapies for the treatment of arthritis.

**Keywords** Gadofluorine M · Cell labeling · Monocytes · MRI

### Introduction

Tissue replacement by stem cell transplants is currently being investigated as a promising approach to treat various diseases, such as myocardial infarction [1], stroke [2], diabetes mellitus [3] and musculoskeletal diseases [4, 5].

Critical questions concerning the fate of the transplanted cells within the host can be answered specifically and non-invasively using cell labeling and cell tracking techniques. Cell labeling with contrast agents for magnetic resonance (MR) imaging provides the ability to monitor the homing and engraftment of the transplanted stem cells non-

invasively with a high anatomical resolution and without irradiation exposure of the host tissue [1–4].

Using MR contrast agents, cells can be either labeled with primarily negatively enhancing  $T_2$  compounds or with primarily positively enhancing  $T_1$  compounds. Iron-oxide based  $T_2$  contrast agents offer the advantage of a high sensitivity for cell tracking [6–12]. Different iron oxide compounds, the relatively larger superparamagnetic iron-oxide particles (SPIO) [7, 9–15] and the relatively smaller ultra-small SPIO (USPIO) [7, 9, 11] have been previously applied for the labeling of numerous different cell types, such as various hematopoietic cells [4, 7], including monocytes [11, 14], carcinoma cells [13, 16], embryonic stem cells [3, 18], mesenchymal stem cells [1, 17, 19] and neurologic stem cells [20]. Labeling of human monocytes with iron oxides has been applied in vivo before to monitor neurodegenerative processes in a mouse model [21].

Positive gadolinium (Gd)-based  $T_1$  contrast agents, on the other hand, provide better anatomical detail on  $T_1$ -weighted sequences [16, 17]. Especially after interventional procedures for stem cell delivery, the signal loss, induced by iron-oxide-based contrast agents, may be difficult to distinguish from image artifacts, such as susceptibility artifacts from air (e.g., delivered via injection devices or open wounds) or postsurgical iron or hemosiderin deposition [8]. The major drawback of  $T_1$  contrast agents with respect to cell labeling, on the other hand, is their lower sensitivity when compared to iron oxides. This puts high expectations on cell labeling techniques, as higher intracellular concentrations or higher relaxivities must be achieved in order to ensure an in vivo cell detection.

Gadofluorine M is a novel gadolinium-based positive  $T_1$  contrast agent. The chemical structure includes a perfluorinated side chain and a sugar moiety, which leads to formation of micelles in aqueous solutions [22, 23]. The amphiphilic character of this substance may be advantageous for its cellular uptake. Furthermore, Gadofluorine M has a higher  $T_1$  relaxivity compared to conventional small molecular Gd chelates [23]. This may diminish the drawback of the limited sensitivity of Gd-based contrast agents when compared to iron-oxide-based contrast agents. Gadofluorine M has been previously utilized for MR assessment of atherosclerotic plaques [22, 24], MR lymphography in rabbits [23] and nerve degeneration in rats [25]. To our knowledge, this is the first study that deals with cell labeling with this novel contrast agent.

The goal of this study was to establish and optimize cell labeling with Gadofluorine M for the depiction of human monocytes with clinical 1.5- and 3-T MR scanners.

## Materials and methods

### Contrast agent

Gadofluorine M is an amphiphilic gadolinium chelate complex (Gd-DO3A derivative), developed by the Schering AG (Berlin, Germany). Gadofluorine M contains a perfluorinated side chain, which provides lipophilicity. The prototype complex also includes a sugar moiety, mannose, which increases the hydrophilicity of the compound [23–25]. For our studies, a fluorescent dye, 1,1'-Bis(sulfobutyl)indocarbocyanine-5-carboxylic acid, was covalently attached to the amino group of the lysine backbone of the Gadofluorine M, exactly at the position of mannose. Thus, the sugar moiety (mannose) was replaced by the cyanine dye. The dye has similar properties in terms of hydrophilicity rendering the GadoM-carbocyanine similar to Gadofluorine M itself. In aqueous solutions, Gadofluorine M forms micelles. Due to this self-aggregation, the compound has a long rotational correlation time and, consequently, high proton relaxivities that thus far have only been obtained with macromolecular complexes. Both the original Gadofluorine M and the fluorescent Gadofluorine M-Cy have a molecular weight of 1,528 Da and an  $r_1$  relaxivity of  $17.4 \text{ mM}^{-1} \text{ s}^{-1}$  in blood at 1.5 T and  $37^\circ\text{C}$ . [23]. In addition, Gadofluorine M-Cy exhibited fluorescence with an excitation peak of 521.9 nm and an emission peak of 569.32 nm. Both contrast agents were supplied as an aqueous solution with a concentration of 250 mmol Gd/l.

### Cell culture and cell labeling

Human monocytes were obtained from the continuously growing histiocytic lymphoma cell line, U937 [American Type Culture Collection (ATCC), Manassas, VA] and cultured in RPMI 1640 medium supplemented with 10% of fetal bovine serum and 1% of penicillin/streptomycin. U937 monocytes were grown in this medium as a non-adherent suspension culture at  $37^\circ\text{C}$  in a humidified 5%  $\text{CO}_2$  atmosphere. For the following in vitro studies, the cells were counted in a Neubauer counting chamber and were seeded in six-well plates:

- (1) In order to determine the optimal concentration of Gadofluorine M for cell labeling,  $5 \times 10^7$  monocytes in 5 ml culture medium were incubated with increasing concentrations of 1.25 mM, 12.5 mM and 125 mM Gadofluorine M for 24 h.
- (2) To determine the optimal time interval of cell incubation with Gadofluorine M,  $5 \times 10^7$  monocytes were incubated with 25 mM Gadofluorine M for 1, 2, 4, 6, 12 and 24 h.
- (3) To determine the minimal detectable cell number, monocytes labeled with 25 mM Gadofluorine M for

12 h were investigated at decreasing cell quantities of  $5.2 \times 10^7$ ,  $2.6 \times 10^7$ ,  $1.3 \times 10^7$ ,  $0.65 \times 10^7$  and  $0.325 \times 10^7$  cells in 0.25 ml Ficoll solution (Sigma-Aldrich, St. Louis, MO). These experiments were performed in triplicate.

- (4) To explore the long-term stability of the labeling,  $5 \times 10^7$  monocytes were incubated with 25 mM Gadofluorine M for 12 h, washed three times and cultured for 1, 3, 5 and 7 days.

After incubation with Gadofluorine M, the cells were washed three times with RPMI 1640 medium by sedimentation (5 min,  $210 \times g$ ,  $25^\circ C$ ). Before and after the labeling procedures, the cell viability was determined by trypan blue exclusion.

Cells were transferred to 1.5-ml test tubes for MR imaging. Selected cell samples in 1 ml RPMI 1640 medium were imaged as centrifuged cell pellets in order to provide a visualization of the maximal possible contrast agent effect of the labeled cells. However, these cell pellets were too small for accurate quantitative analyses. Therefore, all cell samples were subsequently imaged dissolved in 0.25 ml Ficoll solution in order to determine signal-to-noise ratios and  $T_1$  relaxation times of the cells. The isotonic Ficoll solution, prepared with a density of 1.07 g/ml, matched the upper density range of the monocytes and provided a preserved viability of the labeled cells during the scanning procedure.

### MR imaging

MR imaging of the test tubes was performed using a 3-T MR Scanner and a 1.5-T MR scanner (Signa EXCITE HD 3.0 T and Signa EXCITE HD 1.5 T, GE Medical Systems, Milwaukee, WI) and standard circularly polarized quadrature knee coils (Clinical MR Solutions, Brookfield, WI). Cell samples from experiments (1), (2) and (3) were scanned at 1.5 T and 3 T. Since these experiments showed that the labeled cells exhibited higher  $R_1$  values at 1.5 compared to 3 T, subsequent long-term follow-up studies (experiment 4), which focused on the sensitivity of the MR system to detect the Gd-labeled cells, were performed at 1.5 T only. To avoid susceptibility artifacts from the surrounding air in the scans, all samples were placed in a water-containing plastic container and evaluated at room temperature ( $20^\circ C$ ).

Samples with centrifuged cell pellets were investigated with coronal  $T_1$ -weighted spin-echo (SE) 500/16 sequences at 1.5 T and SE 500/15 sequences at 3 T. Samples with cells in Ficoll solution were investigated with axial SE sequences with multiple TR values of 2,000, 1,000, 500 and 250 ms and a TE of 16 or 15 ms at 1.5 T and 3 T, respectively. All sequences were acquired with a field of view (FOV) of  $12 \times 12$  cm, a matrix of  $256 \times 196$  pixels, a slice thickness of 5 mm and one acquisition.

### MR data analysis

Coronal images of centrifuged cells were analyzed qualitatively by determining any visible contrast agent effect in labeled versus non-labeled cell pellets. For quantitative data analysis, the obtained MR images from cells in Ficoll solution were transferred as DICOM images to a SUN/SPARC workstation (Sun Microsystems, Mountain View, CA) and processed by a self-written IDL program (Interactive Data Language by Research Systems, Boulder, CO). The signal intensity (SI) of each test vial and the background noise in frequency encoding direction adjacent to each vial were measured and expressed as signal-to-noise ratios ( $SNR = SI/\text{noise}$ ). In addition,  $T_1$  maps were calculated from four spin-echo images assuming a mono-exponential signal decay with a fixed TE of 15 ms at 3 T and 16 ms at 1.5 T and variable TR values of 2,000, 1,000, 500 and 250 ms using a nonlinear function least-square curve fitting on a pixel-by-pixel basis. The signal intensity for each pixel as a function of time was expressed as follows:  $SI_{\text{pixel } xy}(t) = S_{o(\text{pixel } xy)} [1 - \exp(-t/T_{1\text{pixel } xy})]$ . Care was taken to analyze only data points with signal intensities significantly above the noise level.  $T_1$  relaxation times of cell-bound gadolinium were derived by ROI measurements of the test samples on these maps.  $R_1$  relaxation rates were determined as  $1/T_1$ . Data from triplicate experiments were displayed as means and standard deviations and tested for significant differences with a Student's t-test. A P-value of less than 0.05 was considered significant. In addition, for calculation of  $r_1$  relaxivities of the labeled cells at 1.5 and 3 T, the  $R_1$  relaxation rates were plotted against the Gd concentration in the samples (obtained from spectrometry) using a linear least-squares fit and the KaleidaGraph software program (Synergy Software, Reading, PA). The quality of the fit was determined by the regression coefficient. The  $r_1$  relaxivity corresponded to the slope of the curve.

### Spectrometry

The Gd concentration within all test samples, including samples of labeled cells and non-labeled controls, were determined by inductively coupled plasma atomic emission spectrometry (ICP-AES). The cells in the test samples were dissolved in a microwave (400 W for 55 min) after adding 65%  $HNO_3$  and 30%  $H_2O_2$ . For follow-up studies, the culture medium was analyzed for its Gd-content as well in order to identify a potential release of Gd from the cells. The obtained solutions were nebulized into an argon plasma and then analyzed in the spectrometer (IRIS Advantage; FA. Thermo Jarrell Ash Cooperation, MA). A single investigator (HP), who was blinded with respect to the content of the samples and the corresponding MR data, performed these analyses.


## Fluorescence microscopy

To determine the amount of cellular uptake of the contrast agent,  $5 \times 10^7$  monocytes were incubated in Gadofluorine M-Cy (Gadofluorine M linked to the fluorescent molecule Cy3) at a concentration of 25 mM for 12 h and subsequently washed three times with RPMI 1640 media. Then 50  $\mu$ l of the final solution of the monocytes were spread thinly onto slides and allowed to dry for 5 min at room temperature. After drying, the slides were mounted with Vectashield containing DAPI (Vector Laboratories Inc, Burlingame, CA) and analyzed by confocal microscopy (Zeiss LSM 510 confocal microscope, Thornwood, NY). Images were acquired with a 40 $\times$  objective lens using two excitation lasers: for DAPI staining a UV laser was used (excitation wavelength 351); for the Cy dye, a HeNe1 laser was used (helium-neon, excitation wavelength 543 nm).


## Results

**Optimal concentration of Gadofluorine M for cell labeling**  
Qualitative analysis of cell pellets in test tubes showed a readily visible increase in signal intensity of Gadofluorine M-labeled monocytes on T<sub>1</sub>-weighted MR images compared to non-labeled controls (Fig. 1). This augmented signal intensity of the labeled cells on T<sub>1</sub>-weighted MR images increased after incubation in increasing Gadofluorine M concentrations (Figs. 1 and 2). However, though the intracellular Gd uptake increased linearly after cell incubation with increasing Gadofluorine M concentrations (Fig. 2), the MR signal effect, quantified as SNR values, showed only a minor further increase and reached a plateau for cells that were incubated with more than 25 mM Gd/ml (Fig. 2). Thus, the concentration of 25  $\mu$ M Gd/ml was chosen for subsequent labeling experiments.

**Optimal time interval of gadofluorine M incubation**  
Decreasing the incubation interval to less than 24 h resulted in a decreasing Gadofluorine uptake by the cells



**Fig. 1** Representative coronal T<sub>1</sub>-weighted SE 500/15 MR images of Eppendorf test tubes that contained centrifuged pellets of  $5 \times 10^7$  monocytes after labeling with Gadofluorine M at concentrations of 125 mM (a), 12.5 mM (b) and 1.25 mM Gd (c). The test tube in (d) contains non-labeled control cells




**Fig. 2** Intracellular uptake of Gadofluorine M after incubation of  $5 \times 10^7$  monocytes with increasing contrast agent concentrations for 24 h

and, subsequently, decreasing R<sub>1</sub> relaxation rates (Fig. 3). Therefore, an incubation period of 12 h was considered optimal for a maximal R<sub>1</sub> effect within a minimal time period. The viability of these cells, labeled with 25 mM Gd for 12 h, was  $93 \pm 7\%$ , which was not significantly different from unlabeled controls (viability  $95 \pm 5\%$ ,  $P > 0.05$ ).


**Minimal detectable cell number of monocytes** Cells labeled with Gadofluorine M were detectable at quantities as low as  $5 \times 10^7$  cells/25  $\mu$ l (Figs. 1 and 4), both qualitatively and quantitatively. Fewer labeled cells could not be distinguished from unlabeled control samples ( $P > 0.05$ ).

Of note, the R<sub>1</sub> effect of the T<sub>1</sub>-contrast agent, Gadofluorine, was significantly higher at 1.5 T as opposed to 3 T (Figs. 3 and 4). Accordingly, the r<sub>1</sub> relaxivity of the labeled cells was  $137 \text{ mM}^{-1}\text{s}^{-1}$  at 1.5 T and  $80.5 \text{ mM}^{-1}\text{s}^{-1}$  at 3 T. These data were not significantly different for



**Fig. 3** R<sub>1</sub> relaxation rate of monocytes that were incubated for increasing time intervals with Gadofluorine M at a concentration of 25 mM/ml






**Fig. 4** Dilution series of Gadofluorine M-labeled monocytes at 1.5 and 3 T. The upper part shows axial T1-weighted MR images through Eppendorf test tubes that contained increasing concentrations of Gadofluorine M-labeled monocytes in 0.25 ml Ficoll

solution. Controls refer to samples of unlabeled cells. The graph shows the corresponding R1 relaxation rates and Gd contents of the cell samples. The experiment was performed in triplicates; data are displayed as means +/- SD

Gadofluorine M- and Gadofluorine M-Cy-labeled cells ( $P > 0.05$ ). However, SNR values of the labeled cells were higher at 3 T compared to 1.5 T (Fig. 2), which is most likely due to decreased noise at 3 T.

*Stability of Gadofluorine M labeling over time* Monocytes labeled with 25 mM Gadofluorine M for 12 h were washed and subsequently cultured for 1, 3, 5 or 7 days. The labeled cells showed slowly decreasing R<sub>1</sub> relaxation rates over time (Fig. 5). This could be due to a dilution of the contrast agent in proliferating cells, a slow release of the contrast agent from the cells or a combination of both effects. Of note, ICP-AES studies did not identify measurable quantities of Gadofluorine in the cell culture medium during the follow-up study. However, the quantity



**Fig. 5** R1 relaxation rates of the Gadofluorine M-labeled monocytes on follow-up MR studies

of potentially released contrast agent could be below the detection limit of our spectrometry method (100 pg Gd/ml).


*Correlation of imaging findings with fluorescence microscopy* Uptake of Gadofluorine M-Cy by the monocytes was obvious by confocal microscopy. The contrast agent could be seen as punctate red fluorescence in the cytoplasm of the cells (Fig. 6, a–c). No contrast agent was found in the nucleus of labeled cells. Non-labeled control cells did not have any red fluorescence (Fig. 6, d–f).

## Discussion

These experiments showed that monocytes incubated ex vivo with Gadofluorine M spontaneously internalized this non-particulate, soluble, small molecular contrast agent. Cellular uptake after incubation with Gadofluorine M was sufficient for detection of the cells by T1-weighted sequences and clinical MR scanners.

The uptake of this contrast agent by monocytes could have occurred via three mechanisms: (1) endocytosis, (2)

**Fig. 6** Confocal microscopic images of U-937-cells. (a–c) Gadofluorine-Cy labeled cells, (d–f) non-labeled control cells: a, d DAPI stained cells; b, e Gadofluorine fluorescence; c, f merged images



transmembrane transport or (3) intercalation and cell membrane turnover.

- (1) It is well known that monocytes, in general, have phagocytic properties. U937 are expected to have a high rate of macropinocytosis because they are transformed and incubated in serum containing growth factors. In aqueous solutions, such as the culture medium used to incubate cells with the contrast agent, Gadofluorine M forms relatively large micelles or aggregates about 5 nm in diameter, which may be internalized by endocytosis [23]. The micelle formation of Gadofluorine M occurs only in aqueous solutions (in vitro) and not in blood (in vivo), because the perfluorogroup of the contrast agent shows a hydrophobic interaction with hydrophobic components of proteins (mostly albumin) in the blood. To avoid such hydrophobic interactions and to support micelle formation in vitro, which could potentially improve the phagocytosis of the contrast agent, we incubated cells with the contrast agent in serum-free media. For iron-oxide particles, we found a significant, MR-detectable cellular contrast agent uptake for SPIO particles with a diameter of around 100 nm, but not for USPIO particles with a diameter of 20 nm or less [11]. Thus, though we cannot exclude that a component of phagocytosis contributes to the observed cellular Gadofluorine M uptake, it seems that the size of the Gadofluorine M molecule by itself or even the micelles (5 nm) is too small to explain the observed highly efficient cellular uptake of Gadofluorine M in this study. However, macropinocytosis or endocytosis with uptake via scavenger receptors may be a possible cellular uptake mechanism for Gadofluorine M.
- (2) Specific cell transporters could also facilitate contrast agent internalization. Specific mannose transporters have been found in J774A1 cells (macrophages) [26]. The parental Gadofluorine M includes a mannose molecule, which could have contributed to the observed cellular contrast agent uptake. However, because the measured labeling efficiency was low and the Gadofluorine M-Cy (in which mannose was replaced by the carbocyanine dye) showed a cellular uptake similar to native Gadofluorine M, it seems unlikely that this mechanism is involved.
- (3) Another explanation could be that the hydrophobic perfluorinated side chain of the Gadofluorine M molecule intercalates into the lipids of the plasma membrane and subsequently is taken up due to the high rate of plasma membrane turnover in U 937. This property of the molecule also facilitates contrast agent enrichment in lipid-rich atherosclerotic plaques [22, 24]. However, the apparently punctate intracellular localization of Gadofluorine within monocytes on fluorescence microscopy suggests a compartmentalization of the contrast agent to endosomes, lysosomes or other

vesicular organelles, which is consistent with an active uptake mechanism, most likely endocytosis.

Gadofluorine M is an amphiphilic molecule and, thus, is able to dissolve in aqueous solutions and human plasma. The amphiphilic structure allows the Gadofluorine M molecule to penetrate phospholipid bilayers [23] and to interact with intracellular water protons, which increases  $R_1$  relaxation times and leads to the observed increased signal on  $T_1$ -weighted images. By comparison, conventional Gd-chelates are highly hydrophilic [27] and, thus, are not taken up spontaneously by cells.

Currently established cell labeling techniques are performed with iron-oxide-based contrast agents rather than Gd-based-contrast agents [8, 9, 11, 14, 29]. Iron-oxide particles have been preferred for cell labeling in the past because of their stronger MR signal effect compared to Gd chelates, and, thus, higher sensitivity for detection of the labeled cells. Iron-oxide-based MR contrast agents cause a decreased signal on  $T_2$ -weighted images. A considerable disadvantage of this iron oxide-induced  $T_2$  effect, however, is that magnetic field inhomogeneities can be mistaken for a contrast-agent effect. In addition, these contrast agents are metabolized intracellularly, leading to a slowly decreasing contrast agent effect over time [30] and possible toxicity due to non-physiologic intracellular iron concentrations [31].

Positive  $T_1$  contrast agents, like Gadofluorine, have a low sensitivity compared to iron-oxide-based contrast agents. However,  $T_1$  contrast agents have the important advantage of providing a positive contrast on  $T_1$ -weighted images, which is less likely to be confused with artifacts due to postoperative local signal voids due to metal or air. Gd-based contrast agents such as Gd-DOTA and Gadophrin-2 have been successfully applied in previous cell labeling and in vivo cell-tracking studies [17, 28]. The Gadofluorine M used in this study displays a higher  $r_1$  relaxivity than both Gd-DOTA and Gadophrin-2 and, thus, may compensate to some extent for the inherent lower sensitivity of Gd-based contrast agents compared to iron oxides. Another recently described Gd-based contrast-agent class with high  $r_1$  relaxivity is the Gd-fullerenols [16]. However, these agents are complicated and expensive in their synthesis and can be only internalized into cells with the help of additional assisted labeling techniques. Gadofluorine M has the distinct advantage that it can be incorporated into cells by simple incubation procedures that can be applied without specific knowledge in laboratory techniques.

We recognize several limitations of our study: The current studies have been performed in one cell type, human monocytes, to concentrate on variables related to the contrast agent and to exclude variables by different cell types. The most likely mechanism of cellular uptake is macropinocytosis or endocytosis of the Gadofluorine via scavenger receptors. This would suggest that various other cell types could be

labeled by simple incubation with Gadofluorine M as well. In fact, we are currently performing subsequent studies on stem cells.

In addition, we performed limited follow-up studies, up to 7 days after the labeling procedure. During this time interval, we found a slowly decreasing contrast agent effect of the labeled cells, which was due to dilution of the contrast agent in proliferating cells, clearance of the labeled cells, release of the contrast agent from the cells or a combination of these. Of note, ICP-AES studies did not identify measurable quantities of Gadofluorine in the cell culture medium during the follow-up study for 7 days. However, the quantity of potentially released contrast agent could be below the detection limit of our spectrometric method. Further studies are needed to determine if and when the MR signal effects of Gadofluorine M-labeled cells disappear. This will be dependent on the investigated cell type, the initial Gd uptake and the proliferation rate of the investigated cells. Finally, if any cell type could internalize Gadofluorine M spontaneously, this raises the question of whether such a spontaneous internalization

could also occur *in vivo*. According to our results, the cellular Gadofluorine M uptake occurred only after exposure of the cells to very high extracellular Gadofluorine M concentrations, which exceeded by far plasma concentrations after intravenous injection of the contrast agent. We incubated cells with Gadofluorine concentrations of 25 mM Gd, which is about 60-fold higher than the Gadofluorine plasma concentration (0.4 mmol Gd/l, considering an intravascular space of 0.05 l/kg) and 300-fold higher than the Gadofluorine concentration in the extravascular, extracellular space (0.08 mmol Gd/l; considering an extravascular space of 0.25 l/kg) after intravenous injection of Gadofluorine at a dose of 0.02 mmol Gd/kg. Further studies are needed to determine whether Gadofluorine is spontaneously internalized by cells *in vivo*.

In summary, we have shown that Gadofluorine M is a promising MR contrast agent for labeling monocytes by incubation *ex vivo*. Potential applications of MR imaging of Gadofluorine M-labeled monocytes include targeting of inflammatory processes or monitoring of stem cell therapies for the treatment of arthritis.

## References

- Kraitchmann DL, Heldman AW, Atalar E, Amado LC, Martin BJ, Pittenger MF, Hare JM, Bulte JW (2003) *In vivo* magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. *Circulation* 107:2290–2293
- Zhang ZG, Jiang Q, Zhang R, Zhang L, Wang L, Arniago P, Ho KL, Chopp M (2003) Magnetic resonance imaging and neurosphere therapy of stroke in rat. *Ann Neurol* 53:259–263
- Soria B, Roche E, Berna G, Leon-Quinto T, Reig JA, Martin F (2000) Insulin-secreting cells derived from embryonic stem cells normalize glycaemia in streptozocin-induced diabetic mice. *Diabetes* 49:157–162
- Daldrup-Link HE, Rudelius M, Piontek G, Metz S, Brauer R, Debus G, Corot C, Schlegel J, Link TM, Peschel C, Rummeny EJ, Oostendorp RA (2005) Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: *in vivo* monitoring with 1.5-T MR Imaging equipment. *Radiology* 234:197–205
- Mao JJ (2005) Stem-cell-driven regeneration of synovial joints *Biol Cell* 97 (5):289–301
- Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, Bryant Jr LH, Bulte JWM (2003) Clinically applicable labeling of mammalian stem cells by combining superparamagnetic iron oxides and transfection agents. *Radiology* 228:480–487
- Daldrup-Link HE, Rudelius M, Oostendorp RA, Jacobs VR, Simon GH, Gooding C, Rummeny EJ (2005) Comparison of iron oxide labeling properties of hematopoietic progenitor cells from umbilical cord blood and from peripheral blood for subsequent *in vivo* tracking in a xenotransplant mouse model. *Acad Radiol* 12:502–510
- Bulte JW, Kraitchman DL (2004) Iron oxide MR contrast agents for molecular and cellular imaging. *NMR Biomed* 17:484–499
- Daldrup-Link HE, Rudelius M, Oostendorp RA, Settles M, Piontek G, Metz S, Rosenbrock H, Keller U, Heinzmann U, Rummeny EJ, Schlegel J, Link TM (2003) Targeting of hematopoietic progenitor cells with MR contrast agents. *Radiology* 228:760–767
- Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY, Read EJ, Frank JA (2004) Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. *Blood* 104:1217–1223
- Metz S, Bonaterra G, Rudelius M, Settles M, Rummeny EJ, Daldrup-Link HE (2004) Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents *in vitro*. *Eur Radiol* 14:1851–1858
- Foster-Gareau P, Heyn C, Alejski A, Rutt BK (2003) Imaging single mammalian cells with a 1.5 T clinical MRI scanner. *Magn Reson Med* 49:968–971
- Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA (2003) Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. *Transplantation* 76:1123–1130
- Matuszewski L, Persigehl T, Wall A, Schwindt W, Tombach B, Fobker M, Poremba C, Ebert W, Heindel W, Bremer C (2005) Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. *Radiology* 235:155–161
- Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Zywicke H, Miller B, van Gelderen P, Moskowitz BM, Duncan ID, Frank JA (2001) Magnetodendrimers allow endosomal magnetic labeling and *in vivo* tracking of stem cells. *Nat Biotechnol* 19:1141–1147



16. Anderson SA, Lee KK, Frank JA (2006) Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. *Invest Radiol* 41(3):332–338
17. Daldrup-Link HE, Rudelius M, Metz S, Piontek G, Pichler B, Settles M, Heinzmann U, Schlegel J, Oostendorp RA, Rummeny EJ (2004) Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. *Eur J Nucl Med Mol Imaging* 31(9):1312–1321, Sep
18. Hoehn M, Kustermann E, Blunk J, Wiedermann D, Trapp T, Wecker S, Focking M, Arnold H, Hescheler J, Fleischmann BK, Schwandt W, Buhrle C (2002) Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. *Proc Natl Acad Sci USA* 99:16267–16272
19. Arbab AS, Yocum GT, Wilson LB, Parwana A, Jordan EK, Kalish H, Frank JA (2004) Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. *Mol Imaging* 3:24–32
20. Bulte JW, Zhang S, van Gelderen P, Herynek V, Jordan EK, Duncan ID, Frank JA (1999) Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. *Proc Natl Acad Sci USA* 96:15256–15261
21. Zelvianskaya ML, Nelson JA, Poluektova L, Uberti M, Mellon M, Gendelman HE, Boska MD (2003) Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. *J Neurosci Res* 73:284–295
22. Barkhausen J, Ebert W, Heyer C, Debatin JF, Weinmann HJ (2003) Detection of atherosclerotic plaque with Gadofluorine-enhanced magnetic resonance imaging. *Circulation* 108:605–609
23. Misselwitz B, Platzek J, Weinmann HJ (2004) Early MR lymphography with gadofluorine M in rabbits. *Radiology* 231:682–688
24. Sirol M, Itskovich VV, Mani V, Aguinaldo JG, Fallon JT, Misselwitz B, Weinmann HJ, Fuster V, Toussaint JF, Fayad ZA (2004) Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. *Circulation* 109:2890–2896
25. Bendszus M, Wessig C, Schutz A, Horn T, Kleinschnitz C, Sommer C, Misselwitz B, Stoll G (2005) Assessment of nerve degeneration by gadofluorine M-enhanced magnetic resonance imaging. *Radiology* 57:388–395
26. Park KH, Sung WJ, Kim S, Kim DH, Akaike T, Chung HM (2005) Specific interaction of mannoseylated glycopolymers with macrophage cells mediated by mannose receptor. *J Biosci Bioeng* 99:285–289
27. Merbach A, Toth E (2001) The chemistry of contrast agents in medical Magnetic resonance imaging. Wiley, Chichester, UK
28. Rudelius M, Daldrup-Link HE, Heinzmann U, Piontek G, Settles M, Link TM, Schlegel J (2003) Highly efficient paramagnetic labelling of embryonic and neuronal stem cells. *Eur J Nucl Med Mol Imaging* 30:1038–1044
29. Weissleder R, Cheng HC, Bogdanova A, Bogdanov Jr A (1997) Magnetically labeled cells can be detected by MR imaging. *J Magn Reson Imaging* 7:258–263
30. Riviere C, Boudghene FP, Gazeau F, Roger J, Pons JN, Laissy JP, Allaire E, Michel JB, Letourneur D, Deux JF (2005) Iron oxide nanoparticle-labeled rat smooth muscle cells: cardiac MR imaging for cell graft monitoring and quantitation. *Radiology* 235:959–967
31. Kostura L, Kraitchman DL, Mackay AM, Pittenger MF, Bulte JW (2004) Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. *NMR Biomed* 17:513–517